BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37173893)

  • 1. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
    Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
    March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
    Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Low Muscle Mass on Hepatocellular Carcinoma Patients Undergoing Transcatheter Liver-Directed Therapies: Systematic Review & Meta-Analysis.
    Chen YC; Kuo MH; Hsu CS; Kao IT; Wu CY; Tseng CW; Shao SC
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.
    Guan J; Yang Q; Chen C; Wang G; Zhu H
    EXCLI J; 2021; 20():1-16. PubMed ID: 33510588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
    Sawada K; Saitho Y; Hayashi H; Hasebe T; Nakajima S; Ikuta K; Fujiya M; Okumura T
    JGH Open; 2019 Aug; 3(4):329-337. PubMed ID: 31406927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Meyer HJ; Strobel A; Wienke A; Surov A
    Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
    Meyer HJ; Wienke A; Surov A
    Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and mortality risk of low skeletal muscle mass in critically ill patients: an updated systematic review and meta-analysis.
    Yang H; Wan XX; Ma H; Li Z; Weng L; Xia Y; Zhang XM
    Front Nutr; 2023; 10():1117558. PubMed ID: 37252244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial Brachytherapy for Hepatocellular Carcinoma: Analysis of Prognostic Factors for Overall Survival and Progression-Free Survival and Application of a Risk Stratification Model.
    Thormann M; Heitmann F; Wrobel V; Heinze C; March C; Hass P; Damm R; Surov A; Pech M; Omari J
    Dig Dis; 2023; 41(6):957-966. PubMed ID: 37385234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
    Meyer HJ; Wienke A; Zamsheva M; Surov A
    Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low skeletal muscle mass and post-operative complications after surgery for liver malignancies: a meta-analysis.
    Thormann M; Omari J; Pech M; Damm R; Croner R; Perrakis A; Strobel A; Wienke A; Surov A
    Langenbecks Arch Surg; 2022 Jun; 407(4):1369-1379. PubMed ID: 35583832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low skeletal muscle mass in cholangiocarcinoma treated by surgical resection. A meta-analysis.
    Surov A; Pech M; Omari J; Melekh B; March C; Perrakis A; Wienke A
    HPB (Oxford); 2022 Jul; 24(7):997-1006. PubMed ID: 34906379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis.
    Jiang C; Wang Y; Fu W; Zhang G; Feng X; Wang X; Wang F; Zhang L; Deng Y
    Front Nutr; 2022; 9():978110. PubMed ID: 36590214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.
    Huiskamp LFJ; Chargi N; Devriese LA; May AM; Huitema ADR; de Bree R
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
    Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
    J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis.
    Hu L; Zheng Y; Lin J; Shi X; Wang A
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102061. PubMed ID: 36473632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: A systematic review and meta-analysis.
    Meyer HJ; Wienke A; Surov A
    Nutrition; 2021; 91-92():111417. PubMed ID: 34399402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis.
    Luo J; Gao B; Lin Z; Fan H; Ma W; Yu D; Yang Q; Tian J; Yang X; Li B
    Front Oncol; 2022; 12():1010726. PubMed ID: 36620586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.